HUE028579T2 - New combination - Google Patents
New combination Download PDFInfo
- Publication number
- HUE028579T2 HUE028579T2 HUE12813324A HUE12813324A HUE028579T2 HU E028579 T2 HUE028579 T2 HU E028579T2 HU E12813324 A HUE12813324 A HU E12813324A HU E12813324 A HUE12813324 A HU E12813324A HU E028579 T2 HUE028579 T2 HU E028579T2
- Authority
- HU
- Hungary
- Prior art keywords
- benazepril
- mely mely
- layer
- pimobendan
- fixed dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Edible Oils And Fats (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195015 | 2011-12-21 | ||
| EP12185714 | 2012-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028579T2 true HUE028579T2 (en) | 2016-12-28 |
Family
ID=47552987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12813324A HUE028579T2 (en) | 2011-12-21 | 2012-12-19 | New combination |
| HUE15193269A HUE035830T2 (en) | 2011-12-21 | 2012-12-19 | New combination |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15193269A HUE035830T2 (en) | 2011-12-21 | 2012-12-19 | New combination |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10874618B2 (enExample) |
| EP (3) | EP3034071B1 (enExample) |
| JP (1) | JP6148252B2 (enExample) |
| CN (1) | CN104010632B (enExample) |
| AU (1) | AU2012357795B2 (enExample) |
| BR (1) | BR112014014896A2 (enExample) |
| CA (1) | CA2858941C (enExample) |
| CL (1) | CL2014001534A1 (enExample) |
| CO (1) | CO6970601A2 (enExample) |
| CY (1) | CY1117086T1 (enExample) |
| DK (2) | DK3034071T3 (enExample) |
| ES (2) | ES2560052T5 (enExample) |
| HR (1) | HRP20151347T1 (enExample) |
| HU (2) | HUE028579T2 (enExample) |
| MX (1) | MX365621B (enExample) |
| NO (1) | NO3034071T3 (enExample) |
| PL (2) | PL2793866T5 (enExample) |
| PT (1) | PT3034071T (enExample) |
| RS (1) | RS54475B1 (enExample) |
| RU (1) | RU2014129508A (enExample) |
| SI (1) | SI2793866T1 (enExample) |
| WO (1) | WO2013092673A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| RS54475B1 (sr) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | Nova kombinacija |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| JP6272475B2 (ja) | 2013-07-19 | 2018-01-31 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 |
| CN110721164B (zh) * | 2013-12-04 | 2024-09-17 | 勃林格殷格翰动物保健有限公司 | 匹莫苯的改善的药物组合物 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN112618505B (zh) * | 2020-12-30 | 2022-11-15 | 南京朗博特动物药业有限公司 | 一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364646A (en) | 1990-01-10 | 1994-11-15 | Dr. Karl Thomae Gmbh | Oral pharmaceutical forms of pimobendan |
| US6162802A (en) | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| WO2002049645A1 (en) * | 2000-12-18 | 2002-06-27 | Novartis Ag | Therapeutic combination of amlodipine and benazepril |
| AU2003217916A1 (en) | 2002-03-08 | 2003-09-22 | Teva Pharmeceuticals Usa, Inc. | Stable formulations of angiotensin converting enzyme (ace) inhibitors |
| CO5400144A1 (es) | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| AU2004281541B2 (en) * | 2003-10-20 | 2008-05-01 | Novartis Ag | Tbenazpril and amlodipine for reducing cardiovascular morbidity |
| GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) * | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| JP2005281283A (ja) | 2004-03-31 | 2005-10-13 | Akira Matsumori | ベンズイミダゾール系薬剤の併用医薬 |
| US20080268049A1 (en) * | 2005-02-11 | 2008-10-30 | Dhaliwal Mona | Stable Solid Dosage Forms of Amlodipine and Benazepril |
| JP2010500374A (ja) * | 2006-08-08 | 2010-01-07 | エーシーシーユー−ブレイク テクノロジーズ，インク． | 複数の活性セグメントを含む薬剤の錠剤 |
| AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| FR2917975B1 (fr) | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| WO2010055119A2 (en) | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| WO2010097501A2 (en) | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
| WO2011111066A2 (en) | 2010-03-12 | 2011-09-15 | Connexios Life Sciences Pvt. Ltd. | Composition and uses thereof |
| RS54475B1 (sr) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | Nova kombinacija |
-
2012
- 2012-12-19 RS RS20150850A patent/RS54475B1/sr unknown
- 2012-12-19 NO NO15193269A patent/NO3034071T3/no unknown
- 2012-12-19 ES ES12813324T patent/ES2560052T5/es active Active
- 2012-12-19 PL PL12813324.6T patent/PL2793866T5/pl unknown
- 2012-12-19 HU HUE12813324A patent/HUE028579T2/en unknown
- 2012-12-19 EP EP15193269.6A patent/EP3034071B1/en active Active
- 2012-12-19 EP EP17199031.0A patent/EP3320894A1/en not_active Withdrawn
- 2012-12-19 US US14/366,900 patent/US10874618B2/en active Active
- 2012-12-19 JP JP2014547959A patent/JP6148252B2/ja active Active
- 2012-12-19 CN CN201280062716.3A patent/CN104010632B/zh active Active
- 2012-12-19 EP EP12813324.6A patent/EP2793866B2/en active Active
- 2012-12-19 PL PL15193269T patent/PL3034071T3/pl unknown
- 2012-12-19 HR HRP20151347TT patent/HRP20151347T1/hr unknown
- 2012-12-19 BR BR112014014896A patent/BR112014014896A2/pt active Search and Examination
- 2012-12-19 DK DK15193269.6T patent/DK3034071T3/en active
- 2012-12-19 HU HUE15193269A patent/HUE035830T2/en unknown
- 2012-12-19 ES ES15193269.6T patent/ES2656412T3/es active Active
- 2012-12-19 PT PT151932696T patent/PT3034071T/pt unknown
- 2012-12-19 AU AU2012357795A patent/AU2012357795B2/en active Active
- 2012-12-19 RU RU2014129508A patent/RU2014129508A/ru unknown
- 2012-12-19 CA CA2858941A patent/CA2858941C/en active Active
- 2012-12-19 WO PCT/EP2012/076100 patent/WO2013092673A2/en not_active Ceased
- 2012-12-19 DK DK12813324.6T patent/DK2793866T4/da active
- 2012-12-19 SI SI201230374T patent/SI2793866T1/sl unknown
- 2012-12-19 MX MX2014007700A patent/MX365621B/es active IP Right Grant
-
2014
- 2014-06-03 CO CO14118785A patent/CO6970601A2/es active IP Right Grant
- 2014-06-11 CL CL2014001534A patent/CL2014001534A1/es unknown
-
2015
- 2015-12-30 CY CY20151101200T patent/CY1117086T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012357795B2 (en) | New combination | |
| US7427414B2 (en) | Modified release oral dosage form using co-polymer of polyvinyl acetate | |
| US20120207825A1 (en) | Pharmaceutical compositions for reducing alcohol-induced dose dumping | |
| US20040043996A1 (en) | Controlled release formulation of lamotrigine | |
| EP2275093A2 (en) | Pharmaceutical formulation | |
| MX2012006241A (es) | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. | |
| HUE029680T2 (en) | Dispensing systems containing weakly basic active ingredients and organic acids | |
| US20110229564A1 (en) | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof | |
| EP2533766B1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| JPWO2014171542A1 (ja) | 放出制御製剤 | |
| US20080118554A1 (en) | Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant | |
| US10835497B2 (en) | Rivastigmine-containing sustained-release pharmaceutical composition | |
| NZ625506B2 (en) | Compositions For Treatment of Heart Failure in Dogs. |